Allergan Aesthetics Gains Health Canada Approval for Boey® as First Botulinum Serotype E Neurotoxin

A novel biologics approval pathway has been navigated for the first time in aesthetic neurotoxin science: Allergan Aesthetics, an AbbVie company, has received Health Canada approval for Boey® (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adult patients. Canada becomes the first jurisdiction globally to approve a botulinum neurotoxin based on serotype E for aesthetic use, setting a regulatory precedent that biologics manufacturers and QA leads in this space will need to track closely.

The distinction matters beyond the commercial milestone. Serotype E is pharmacologically distinct from the serotype A and B products already on the market, presenting a different mechanism of action at the neuromuscular junction. For quality and regulatory teams, that distinction translates into novel characterisation requirements, reference standard development, and potency assay validation work that does not map directly onto existing serotype A frameworks. How Health Canada structured its biologics review for a first-in-class serotype will be closely examined by regulatory affairs leads preparing dossiers in other jurisdictions, given that trenibotulinumtoxinE is currently under review for approval in multiple other countries.

The clinical basis for approval rests on two randomised, multi-centre, double-blind, placebo-controlled Phase 3 trials (M21-500 and a second study) evaluating efficacy and safety in adults with moderate to severe glabellar lines. The product's differentiated profile centres on rapid onset, results observable as early as eight hours post-injection, and a short duration of approximately two to three weeks, a profile that introduces distinct stability and cold-chain considerations relative to longer-acting serotype A products.

From a manufacturing standpoint, introducing a new serotype into a biologics fill-finish environment raises questions around contamination control strategy, in-process testing, and batch release criteria. Allergan Aesthetics has not disclosed the manufacturing site or detailed process parameters, but QA directors at contract and captive biologics facilities will note that a serotype E product requires independent reference materials and release assays; existing BOTOX Cosmetic® infrastructure cannot simply be repurposed. The company has confirmed that BOTOX Cosmetic® (onabotulinumtoxinA) is the only neurotoxin clinically tested for sequential use following Boey® treatment, a data point relevant to clinical protocol design but also to labelling and post-market surveillance obligations.

Allergan Aesthetics has indicated that healthcare professional training will precede commercial launch, with market entry expected within the coming months in Canada.

Regulatory submissions in additional markets will test whether Health Canada's serotype E approval pathway becomes a reference model or whether other agencies impose distinct characterisation and comparability requirements before granting market authorisation.

Source: AbbVie News Center via PRNewswire, 23 June 2026.